The Company generates revenue primarily through licensing its products, recognizing license revenue in accordance with ASC 606 revenue recognition standards. It invests in research and development programs, including EVO756, EVO301, as well as early-stage programs such as discovery research and pre-clinical development. The Company recognizes revenue when performance obligations to customers are fulfilled.

Evommune Inc’s Comment on Sales, Marketing and Customers

EVMN's Stock Performance relative to it's Customers

EVMN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Evommune Inc	271.72	0.00	0.00	48
SUBTOTAL	0.00	0.00	0.00	-

Sources: Evommune Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Evommune Inc’s corporate clients.
For your research, we’ve provided 9 tables on Evommune Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.